UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/511,891	06/09/2005	Bud G. Harmon	32-02	6483
23713 7590 04/16/2007 GREENLEE WINNER AND SULLIVAN P C 4875 PEARL EAST CIRCLE SUITE 200 BOULDER, CO 80301			EXAMINER	
			SAYALA, CHHAYA D	
			ART UNIT	PAPER NUMBER
			1761	
SHORTENED STATUTOR	Y PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE	
3 MONTHS 04/16/2007		04/16/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

		11/			
	Application No.	Applicant(s)			
	10/511,891	HARMON ET AL.			
Office Action Summary	Examiner	Art Unit			
	C. SAYALA	1761			
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the	correspondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.11 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period v - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATIO 36(a). In no event, however, may a reply be tin will apply and will expire SIX (6) MONTHS from , cause the application to become ABANDONE	N. mely filed the mailing date of this communication. ED (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 3/14	<u>% 3/15/2007</u> .				
2a) This action is FINAL . 2b) ☐ This	This action is FINAL . 2b)⊠ This action is non-final.				
·	☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is				
closed in accordance with the practice under E	Ex parte Quayle, 1935 C.D. 11, 4	53 O.G. 213.			
Disposition of Claims					
4) Claim(s) 1 and 3-11 is/are pending in the applied 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) 1, 3-11 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or	vn from consideration.				
Application Papers					
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomplished any accomplished any objection to the Replacement drawing sheet(s) including the correct and the option of the second state of the second	epted or b) objected to by the drawing(s) be held in abeyance. Se ion is required if the drawing(s) is ob	e 37 CFR 1.85(a). njected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119		,			
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:	ate			

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submissions filed on 3/14 & 3/15/2007 have been entered.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1, 3-11 are rejected under 35 U.S.C. 103(a) as being unpatentable over Harmon et al. (US Patent 6235339) in view of Roets (US Patent 4559146) and the admitted prior art in the specification at page 5, lines 6-10, and further in view of Kaczmarek et al. (US Patent 4983297), Fullerton et al. (US Patent 4085041) and Othmer (US Patent 3772187).

Harmon et al. teach that using magnesium chloride instead of the prior art usage of iron chloride is beneficial. (See col. 4, lines 28-41). Harmon et al. teach treating organic waste streams containing animal fat, blood, tissue, etc. The amount of

magnesium chloride: 0.5-5.0% by vol. The patent does not teach aeration. It does teach the magnesium chloride-dissolved air flotation process and the removal of the flocculated material. See col. 3, lines 60-67. The patent also teaches reducing the BOD to less than about 750 ppm. See claim 5.

Roets teaches chemically treating proteinaceous waste water, and then aeration of the waste water. Foam formed is removed during the aeration. See the claims that describe the steps. In this regard, Fullerton et al. teach at col. 2, lines 1-10, that oxygen aeration produces foam that is typically undesirable, which rises to the top and is removed.

The specification discloses that the aeration is performed as is known in the art. The prior art listed therein is said to accomplish the aeration. Othmer teaches coagulating and flocculating waste first before aeration, and then using a Venturi system for the aeration (col. 2, line 4, col. 4, lines 48-50) to reduce BOD (line 56). As for the time for aeration, lines 15-25 (col. 4) teaches some of the parameters determine this. However, aeration time will depend on the degree of reduction of BOD required in the effluent and the nature of the BOD. See also col. 10, lines 42-44. Kaczmarek et al., drawn to waste water, is used here only to show that aerobic waste treatment also is used because the method decreases BOD. See col. 4, lines 46-49. With regard to claim 10, note that Harmon teaches treatment with the oxidizing agent "may be necessary if any color or residual material remains in the fluid fraction". Therefore to eliminate such a step would have been obvious based on Harmon's teaching alone.

It would have been obvious to combine the chemical treatment of proteinaceous wastes of Harmon et al. with an aeration step as shown by Roets, which is also drawn to the same endeavor, and uses iron chloride instead of magnesium chloride, which is followed thereafter by aeration. Since Kaczmarek et al. teach that aeration also reduces BOD in waste treatment, then such disclosure provides the motivation to combine Harmon et al's magnesium chloride treatment to reduce BOD with aeration to reduce BOD, in the same manner as Roet, i.e. chemical treatment followed by aeration. In doing so, it would naturally flow from prior art teachings that the BOD would have been reduced to the same extent. See American Infra-Red Radiant Co. v Lambert Indus., Inc., 360 F.2d 977, 986 [149 USPQ 722 (CCPA 1958)], (8th Cir.) (quoting Application of Libby, 255 F.2d 412 [118 USPQ 194 (CCPA 1958)], CERT. DENIED. 385 U.S. 920 [151 USPQ 757](1966). It would also have been obvious to remove any foam formation for the reasons shown by Fullerton et al. and Roets. To use any aeration system, including the Venturi system as shown by Othmer would have been obvious, since no unobviousness in this regard has been established herein.

Response to Arguments

Applicant's arguments filed 3/14 & 3/15/07 have been fully considered but they are not persuasive.

At pages 6-7, applicant has traversed the rejection in essence, by taking the position that the combination can only have been made based on hindsight reasoning. In response to applicant's argument that the examiner's conclusion of obviousness is

based upon improper hindsight reasoning, it must be recognized that any judgment on obviousness is in a sense necessarily a reconstruction based upon hindsight reasoning. But so long as it takes into account only knowledge which was within the level of ordinary skill at the time the claimed invention was made, and does not include knowledge gleaned only from the applicant's disclosure, such a reconstruction is proper. See *In re McLaughlin*, 443 F.2d 1392, 170 USPQ 209 (CCPA 1971).

A review of the references applied show the following

- ❖ Roets teaches clarifying proteinaceous waste water with chemical treatment (FeCl₃) and aeration.
- ❖ Harmon et al. teaches the benefits of using MgCl₂ instead of FeCl₃ and the benefits of substituting one for the other in the reduction of BOD.
- ❖ Therefore, to replace FeCl₃ with MgCl₂ would have been prima facie obvious in Roets.
- Kaczmarek et al. is drawn to waste water treating with aeration and teaches reduction of BOD with this method. One embodiment shows aeration for a day.
- Othmer teaches an aeration time from 30 minutes to several hours.
- Othmer teaches that the aeration time depends on whether coagulating and deflocculating agents were used.
- The specification discloses that "The time of aeration depends on the beginning BOD and COD levels of the effluent to be treated and the

Application/Control Number: 10/511,891

Art Unit: 1761

desired finals levels. This can be determined without undue experimentation." (Page 5, specification).

Thus aeration time depends on the nature of the BOD, the BOD levels in the effluent to start with and the final levels desired, and whether coagulating and deflocculating agents were used. And all of these factors can be used to determine aeration time, without undue experimentation.

Therefore, when Harmon et al. is combined with references that teach chemical treatment with iron chloride and aeration, and the iron chloride is substitute with magnesium chloride, and the aeration time calculated based on all the factors above, without undue experimentation, then the aeration time would be obvious. Also, it is well settled that a patent cannot be properly granted for [an invention] which would flow naturally from the teaching of the prior art. American Infra-Red Radiant Co. v Lambert Indus., Inc., 360 F.2d 977, 986 [149 USPQ 722 (CCPA 1958)], (8th Cir.) (quoting Application of Libby, 255 F.2d 412 [118 USPQ 194 (CCPA 1958)], CERT. DENIED, 385 U.S. 920 [151 USPQ 757](1966). Applicant's remark that aerating the waste stream for a time of about one to seven days provides a BOD level that is reduced more when MgCl₂ is used would have resulted by following the teachings of the applied patents.

As for applicant's statements regarding the addition of the oxidizing agent at page 7, as pointed out above, the addition is not necessary unless removal of color or residual material is necessary. Therefore, the addition of peroxide or hypochlorite is

optional. As for the discussion of the inapplicability of the Kaczmarek, which is disagreed with, Kaczmarek states that "Any conventional aerobic waste water treatment method for decreasing the Biological Oxygen Demand (B.O.D.) level may be used", thus refuting applicant's position. As for the remaining references, applicant has argued each reference in isolation and has extended the argument to reference teachings that were not relied upon. For instance applicant states that Roets does not teach magnesium as its chemical for the chemical treatment. Magnesium is shown by Harmon, and Roets was relied on to show the pattern and advantage of using aeration as a follow-up after chemical treatment.

Conclusion

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no, however, event will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to C. SAYALA whose telephone number is 571-272-1405.

Application/Control Number: 10/511,891 Page 8

Art Unit: 1761

The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

C. SAYALA

Primary Examiner Group 1700.